Rapamycin and Longevity: A Breakthrough Clinical Trial in Healthy People

In March 2026, UT Health San Antonio, one of the leading medical research institutions in the United States, announced the launch of a new clinical trial: testing the effect of rapamycin on healthy aging in people. This announcement, which did not make mainstream headlines, is a groundbreaking moment for the field of geroscience, the study of aging as a biological phenomenon that can be slowed.

The story of rapamycin is one of the most surprising in modern medicine. A drug discovered in soil on Easter Island in 1972, now used to prevent organ transplant rejection, has become the holy grail of longevity researchers. In every living model tested: yeast, worms, flies, mice, it succeeded in extending lifespan. The question that has remained open for 20 years is: will it work in humans too? The new trial from UT Health San Antonio is expected to provide an initial answer.

What is Rapamycin?

Rapamycin, also known as sirolimus, is a molecule with an extraordinary history:

• Origin: Discovered in 1972 in a soil sample from Easter Island (Rapa Nui), hence the name. It is produced by a bacterium called Streptomyces hygroscopicus.
• Current clinical use: FDA-approved for preventing kidney transplant rejection and treating certain rare diseases.
• Mechanism: It inhibits a protein called mTOR (mechanistic Target Of Rapamycin), a central switch that regulates cell growth, protein production, and metabolism.
• Unique property: While many drugs extend lifespan in mice only when started from birth, rapamycin works even when started at an older age.

The transition from an anti-rejection drug to a potential longevity drug is one of the most fascinating stories of drug repurposing, finding new uses for existing drugs.

The Connection to Longevity: mTOR Mechanism and Autophagy

To understand why rapamycin can slow aging, you need to understand mTOR. This protein acts like a central 'growth switch' in the cell:

• When food is available, mTOR is active and instructs the cell to grow, divide, and produce proteins.
• When food is absent (fasting, caloric restriction), mTOR is deactivated. The cell then shifts to a 'maintenance' mode: it breaks down damaged proteins, cleans out malfunctioning organelles, and conserves energy.

This process of cleaning and maintenance is called autophagy, literally 'self-eating'. Cells that undergo autophagy regularly stay younger, accumulate less damage, and function better. Aging, at the cellular level, is largely a failure of autophagy.

Rapamycin mimics the effect of fasting: it inhibits mTOR even when food is present, causing the cell to activate autophagy. Additionally, it affects:

• Senescent cells (zombie cells): Rapamycin reduces the accumulation of aging cells that emit inflammatory signals.
• Immune system: At low doses, it rejuvenates the immune response in the elderly, a surprising finding reported in studies by the company Resilio.
• Mitochondrial function: It improves mitochondrial biogenesis, the creation of new energy-producing organelles.
• Chronic inflammation: It lowers inflammatory markers like IL-6 and TNF-alpha, which increase with age.

Current Evidence

Study 1: ITP Mouse Study, the Landmark Discovery from 2009

The experiment that made rapamycin a star was the Interventions Testing Program (ITP), an NIH project that tested various drugs in genetically diverse mice. Rapamycin extended the lifespan of male mice by 9% and females by 14%, even when treatment started at 600 days of age, equivalent to 60 years in humans. This was the first study to show that lifespan could be extended in older mice with a drug.

Study 2: Mannick et al. on Immune System in the Elderly (2014, 2018)

Researchers from Novartis tested 264 elderly individuals over 65 who received a low dose of a rapamycin analog (RAD001) before a flu vaccine. The treated group showed a 20% better immune response to the vaccine and a 1.7% reduction in respiratory infections over a year. This was the first clinical proof that mTOR inhibition could restore immune function in humans.

Study 3: PEARL Trial, the Leading Trial for UT Health (2020-2023)

A private project called Participatory Evaluation of Aging With Rapamycin for Longevity (PEARL), the first trial of rapamycin in healthy people. 114 participants aged 50-85 received 5-10mg of rapamycin weekly for a year. Results reported in 2024: an 8% improvement in muscle mass, improved grip strength, and reduced inflammatory markers. However, the study was small and not optimally double-blind.

Study 4: Large Dogs, Dog Aging Project

University of Washington is running a trial on 580 large dogs receiving weekly rapamycin. Preliminary results from 2025: a 15% improvement in heart function and improved overall activity levels. Large dogs age quickly and die from the same age-related diseases as humans, making this model particularly relevant.

The New Trial at UT Health San Antonio (2026)

The trial announced on March 25, 2026, is the first large-scale academic clinical trial testing rapamycin as a longevity drug. The protocol is expected to include:

• Dosage: 5mg of rapamycin once a week (low, cyclic dosing), unlike the high daily dose given to organ transplant recipients.
• Duration: 12-24 months.
• Population: Healthy adults aged 55-75.
• Primary endpoints: Biological age based on epigenetic clocks (Horvath, GrimAge), inflammatory markers, physical function (strength, balance, flexibility), cognitive function, sleep quality.
• Funding: A combination of federal grants and philanthropic donations, with no commercial pharmaceutical company.

Why Rapamycin Became the Holy Grail

In the longevity field, there are dozens of candidates: metformin, NMN, NR, spermidine, fisetin, quercetin. So why did rapamycin achieve special status? Three main reasons:

1. Exceptional consistency across models: While other supplements showed conflicting results between labs, rapamycin extended lifespan in every lab and every mouse strain tested. This suggested a real mechanism, not a methodological flaw.
2. Clear mechanism of action: Most supplements sold in the industry lack a well-defined mechanism, or the mechanism is still debated. mTOR, in contrast, is one of the most well-documented pathways in biology.
3. Effect even at an older age: Most anti-aging supplements work only if started in youth. Rapamycin showed an effect even when started at an older age, making it practically relevant.

Additionally, rapamycin has a practical advantage: it is a generic, cheap, and accessible drug. At a cost of about $100-300 per month, it is within reach for those willing to get an off-label prescription.

The Dark Side: Side Effects and Risks

Rapamycin is not without risks. At high doses, as given to organ transplant recipients, it causes:

• Immunosuppression, a 15-25% increase in respiratory and urinary infections.
• Metabolic disturbances, a 30-50% increase in blood lipids, and elevated blood sugar levels.
• Mouth ulcers in 25-40% of patients.
• Lung function disorders, a low but documented risk of pneumonitis.
• Impaired wound healing, important before surgeries.

The reason longevity researchers believe healthy people can benefit without harm is low, cyclic dosing. Instead of 1-5mg daily, they give 5mg once a week. This is expected to activate autophagy strongly enough to create an anti-aging effect, without long-term immune suppression.

However, this assumption has not yet been proven on a large scale. The UT Health San Antonio trial is precisely the attempt to validate it.

The Gap Between Mice and Humans

An important warning: mice are not small humans. Rapamycin's great success in mice does not guarantee success in humans, for many reasons:

• Lab mice live in a sterile environment, eat a uniform diet, and are not exposed to routine infections. In humans, mild immunosuppression can be more problematic.
• Different metabolic systems: Mice rely more on fat oxidation, humans more on glucose.
• Different lifespan: A 14% extension in a mouse (2-year lifespan) equals 3-4 months. A 14% extension in a human (80-year lifespan) equals 11 years. There is no guarantee the effect is linear.
• Response time: A study in humans would take many years to show an effect on lifespan, so researchers rely on biological age markers, epigenetic markers, inflammatory markers, and physical function.

The 'Biohacker' Community Ahead of Science

While academia moves slowly, a large community of people has been taking rapamycin off-label for five years. In podcasts by Peter Attia and David Sinclair, the prevailing view is that taking 5-6mg of rapamycin weekly is safe and potentially beneficial for middle-aged and older people.

Companies like AgelessRx and Healthspan offer off-label prescriptions for rapamycin via telemedicine, with blood marker monitoring. But this is still an uncontrolled experiment on hundreds of thousands of people. Without systematic data, there is no way to know if there is a real effect, what the real risk is, and who truly benefits.

Should You Take Rapamycin?

The short answer: Not until results from the UT Health trial are available. The reasons:

If you are a healthy person under 50

The potential risk—mild immunosuppression, metabolic effects—outweighs the expected benefit. Your body is already functioning well.

If you are over 65 with health issues

Here the decision is complex. The benefit may be large enough to justify a trial, but only under the supervision of a doctor familiar with the treatment and able to monitor.

If you have an autoimmune disease

This might actually be a legitimate use. Rapamycin is an immunosuppressant, and there are promising studies on its use in autoimmune diseases. But not as an anti-aging drug, rather as a specific disease treatment.

If you are a candidate for the clinical trial

This is the best way to be exposed to rapamycin: in a controlled environment, with close medical monitoring, and contributing to science. UT Health San Antonio will accept participants aged 55-75. It is recommended to check their website.

What to Do Now

1. Activate autophagy naturally. Fasting for 14-16 hours a day, or a 24-hour fast once a week, activates the same pathways that rapamycin does. No side effects, no cost, and solid evidence.
2. Moderate caloric restriction. Reducing calorie intake by 10-15% activates SIRT1 and AMPK, and suppresses mTOR naturally.
3. Intense physical activity. HIIT training, resistance training, and regular aerobic exercise mimic the metabolic effects of mTOR inhibition.
4. Quality sleep. During deep sleep, the body activates autophagy and repair mechanisms. Poor sleep negates much of the benefit of any longevity drug.
5. Follow the trial results. By 2028, preliminary results from the UT Health trial will be available. If they show a significant effect on biological age, the market will move quickly. If they show significant side effects, the movement will slow.

The Broader Perspective

The UT Health San Antonio trial is more than just a study on a drug. It is a milestone for the geroscience agenda: the field that argues aging itself is a treatable process, not just a sequence of unrelated diseases. If the trial shows positive results, it will change how regulators, doctors, and insurance companies think about aging.

It is important to remember: no single drug will solve aging. Aging is a system of nine interconnected biological processes, what researchers call The Hallmarks of Aging. Rapamycin addresses some of them, but not all. The complete solution will require a combination of drugs (rapamycin, senolytics, metformin), lifestyle (diet, exercise, sleep), and perhaps in the future, cellular therapies.

Nevertheless, this trial marks the end of the era of pills for humans without data. After 20 years of promises in the anti-aging field, answers are finally coming. If rapamycin truly slows aging in humans, we will know. If not, we will know that too. And that alone will be a huge achievement for science.

References:
UT Health San Antonio - Rapamycin Clinical Trial Announcement
NIA Interventions Testing Program - Rapamycin in Mice